The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer

The antiandrogen enzalutamide (Enz) has improved survival in castration resistant prostate cancer (CRPC) patients. However, most patients eventually develop Enz resistance that may involve inducing the androgen receptor (AR) splicing variant 7 (ARv7). Here we report that high expression of monoamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Keliang, Luo, Jie, Yeh, Shuyuan, You, Bosen, Meng, Jialin, Chang, Philip, Niu, Yuanjie, Li, Gonghui, Lu, Changxue, Zhu, Yezi, Antonarakis, Emmanuel S., Luo, Jun, Huang, Chi-Ping, Xu, Wanhai, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264333/
https://www.ncbi.nlm.nih.gov/pubmed/32483206
http://dx.doi.org/10.1038/s41467-020-15396-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264333/
https://www.ncbi.nlm.nih.gov/pubmed/32483206
http://dx.doi.org/10.1038/s41467-020-15396-5

Ejemplares similares